TY - JOUR
T1 - Proposal for a regulation on health technology assessment in Europe–opinions of policy makers, payers and academics from the field of HTA
AU - Vella Bonanno, Patricia
AU - Bucsics, Anna
AU - Simoens, Steven
AU - Martin, Antony P.
AU - Oortwijn, Wija
AU - Gulbinovič, Jolanta
AU - Rothe, Celia
AU - Timoney, Angela
AU - Ferrario, Alessandra
AU - Gad, Mohamed
AU - Salem, Ahmed
AU - Hoxha, Iris
AU - Sauermann, Robert
AU - Kamusheva, Maria
AU - Dimitrova, Maria
AU - Petrova, Guenka
AU - Laius, Ott
AU - Selke, Gisbert
AU - Kourafalos, Vasilios
AU - Yfantopoulos, John
AU - Magnusson, Einar
AU - Joppi, Roberta
AU - Jakupi, Arianit
AU - Bochenek, Tomasz
AU - Wladysiuk, Magdalene
AU - Furtado, Claudia
AU - Marković-Peković, Vanda
AU - Mardare, Ileana
AU - Meshkov, Dmitry
AU - Fürst, Jurij
AU - Tomek, Dominik
AU - Cortadellas, Merce Obach
AU - Zara, Corrine
AU - Haycox, Alan
AU - Campbell, Stephen
AU - Godman, Brian
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/5/4
Y1 - 2019/5/4
N2 - Introduction: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): ‘Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU’. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency. There were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision-making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it is important that a balanced, improved outcome is achieved for all stakeholders. If not approved, the extensive contribution and progress attained should be sustained and preserved, and the best alternative solutions found.
AB - Introduction: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): ‘Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU’. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency. There were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision-making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it is important that a balanced, improved outcome is achieved for all stakeholders. If not approved, the extensive contribution and progress attained should be sustained and preserved, and the best alternative solutions found.
KW - EUnetHTA
KW - European legislation
KW - Member States
KW - cross border agreements
KW - joint collaboration on HTA
UR - http://www.scopus.com/inward/record.url?scp=85061826123&partnerID=8YFLogxK
U2 - 10.1080/14737167.2019.1575730
DO - 10.1080/14737167.2019.1575730
M3 - Article
C2 - 30696372
AN - SCOPUS:85061826123
SN - 1473-7167
VL - 19
SP - 251
EP - 261
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 3
ER -